Recent data suggest that intensive therapy followed by a bone marrow antotransplant is effective in advanced intermediate and high-grade non-Hodgkin lymphoma (predominantly large-cell lymphoma). Twelve studies of autotransplants were analyzed to determine outcome. Results compared to data from 29 chemotherapy studies. Complete remission was reported in 53% of autotransplant recipients versus 17% of persons receiving chemotherapy. Two-year disease-free survival was 16 and 2%, respectively. It is uncertain whether these differences indicate superiority of autotransplants or reflect selection biases. Also unknown is whether similar results might not be obtained with similarly intensive treatment without an autotransplant.
Advisory Committee of the International Autologous Bone Marrow Transplant Registry (ABMTR).Autologous bone marrow transplants: Different indications in Europe and North America.Lancet2: 317–318; 1989.
2.
AndersonC.C.; GoldstoneA.H.; SouhamiR.L.;Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.Cancer Chemother. Pharmacol.16: 170–175; 1986.
3.
ArmitageJ.O.Bone marrow transplantation in patients with lymphoma.Blood73: 1749–1758; 1989.
4.
ArmitageJ.O.; JagannathS.; SpitzerG.;High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma.Eur. J. Cancer Clin. Oncol.22: 871–877; 1986.
5.
AuerI.; RibasA.; GaleR.P.What is the role of recombinant colony stimulating factors in bone marrow transplantation.Bone Marrow Transplant6: 79–87; 1990.
6.
BajettaE.; BuzzoniR.; ValagussaP.; BonadonnaG.Mitoxantrone: An active agent in refractory non-Hodgkin's lymphomas.Am. J. Clin. Oncol.11: 100–103; 1988.
7.
CabanillasF.; HagemeisterF.B.; McLaughlinP.;Results of MIME regimen for recurrent or refractory lymphoma.J. Clin. Oncol.5: 407–412; 1987.
8.
CabanillasF.; VelasquezW.S.; McLaughlinP.;Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.Semin. Hematol.25: 47–50; 1988.
9.
ChadhaM.; ShankB.; FuksZ.;Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, “boost” radiation therapy, and autologous bone marrow transplantation.Int. J. Radiat. Oncol. Biol. Phys.14: 407–415; 1988.
10.
CollinsC.; MortimerJ.; LivingstoneR.B.High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies.Cancer63: 228–232; 1989.
11.
ColombatP.; GorinN.C.; LemonnierM.P.;The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphoma.J. Clin. Oncol.8: 630–637; 1990.
12.
DabichL.; LiepmanM.K.Cisplatin, VP-16-213 and MGBG (Methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.Invest. New Drugs6: 231–237; 1988.
13.
DugganD.B.; AndersonJ.R.; DillmanR.;2′ Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: A CALGB phase II study.Med. Pediatr. Oncol.18: 203–206; 1990.
14.
Foss-AbrahamsenA.; LennerP.; HedenusM.;Mitoxantrone in the treatment of patients with non-Hodgkin's lymphoma.Cancer Treat. Rep.71: 1209–1212; 1987.
15.
GaleR.P.; HorowitzM.M.; BiggsJ.C.;for the Advisory Committee of the International Bone Marrow Transplant Registry. Transplant or chemotherapy in acute myelogenous leukemia.Lancet1: 119–122; 1989.
16.
GribbenJ.G.; GoldstoneA.H.; LinchD.C.;Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy.J. Clin. Oncol.7: 1621–1629; 1989.
17.
HoA.D.; Del ValleF.; RuckleH.;Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.Cancer64: 1388–1392; 1989.
18.
HorowitzM.M.; MessererD.; HoelzerD.;Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.Ann. Intern. Med.115: 13–18; 1991.
19.
HurdD.D.; LeBienT.W.; LaskyL.C.;Autologous bone marrow transplantation in non-Hodgkin's lymphoma: Monoclonal antibodies plus complement for ex vivo marrow treatment.Am. J. Med.85: 829–834; 1988.
20.
JacksonD.V.; PowellB.L.; CruzJ.M.;Infusion of etoposide and vincristine in non-Hodgkin's lymphoma.Sel. Cancer Ther.5: 129–136; 1989.
21.
JacksonD.V.Jr.; SpurrC.L.; CaponeraM.E.;Vinblastine infusion in non-Hodgkin's lymphomas: Lack of total cross-resistance with vincristine.Cancer Invest.5: 535–539; 1987.
22.
JonesL.; CotterF.E.; LordD.; NewlandA.C.Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkin's lymphoma.Hematol. Oncol.8: 41–45; 1990.
23.
KumarL.; BajpalV.; DuaH.Vincristine infusion in advanced non-Hodgkin's lymphoma.Indian J. Cancer26: 14–16; 1989.
24.
LachantN.A.; AndersonJ.; GinsbergS.J.;Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and leukemia group B study 7902.Med. Pediatr. Oncol.16: 375–377; 1988.
25.
LiangT.D.; ChanT.K.HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma.Cancer Chemother. Pharmacol.22: 169–171; 1988.
26.
MascretB.; MaraninchiD.; GastautJ.A.;Treatment of malignant lymphoma with high dose of chemo or chemoradiotherapy and bone marrow transplantation.Eur. J. Cancer Clin. Oncol.22: 461–471; 1986.
27.
NicholsC.R.; LoehrerP.J.; GreistA.;Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin.Med. Pediatr. Oncol.16: 12–16; 1988.
28.
O'DonnellM.R.; FormanS.J.; LevineA.M.;Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.Cancer Treat. Rep.71: 187–189; 1987.
29.
OhnoshiT.; HayashiK.; UeokaH.;Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.Cancer Treat. Rep.71: 639–641; 1987.
30.
OsterW.; ForsthuberT.; HennekeuserH.H.;MACOP-B chemotherapy for the treatment of high grade and intermediate grade non-Hodgkin's lymphoma.Blut60: 23–27; 1990.
31.
PetersenF.B.; AppelbaumF.R.; HillR.;Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle.J. Clin. Oncol.8: 638–647; 1990.
32.
PhilipT.; ArmitageJ.O.; SpitzerG.;High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.N. Engl. J. Med.316: 1493–1498; 1987.
33.
PhillipsG.L.; FayJ.W.; HerzigR.H.;The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.Blood75: 831–838; 1990.
34.
RybakM.E.; AndersonJ.R.; PoulinR.F.;Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and leukemia group B study 7972.Cancer Treat. Rep.70: 1233–1234; 1986.
35.
SangsterG.; PattonW.N.; HarrisR.I.;Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfmide, methotrexate and etoposide.Cancer Chemother. Pharmacol.23: 263–265; 1989.
36.
SchillerJ.H.; RitchP.S.; StorerB.; TrumpD.L.A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas.Am. J. Clin. Oncol.12: 502–506; 1989.
SessaC.; ten Bokkel HuinikW.; ClavelM.;A phase II study of Spirogermanium in patient with advanced malignant lymphoma.Invest. New Drugs7: 219–222; 1988.
39.
SkipperH.E.; SchabelF.M.Quantitative and cytokinetic studies in experimental tumor systems. In: HollandJ.; FreiE., eds. Cancer medicine.Philadelphia: Lea and Febiger; 1982: 663–684.
40.
TakagiT.; SakaiC.; OguroM.Intermediate-dose cytosine arabinoside in the treatment of recurrent or refractory non-Hodgkin's lymphoma.Jpn. J. Clin. Oncol.19: 123–126; 1989.
41.
TakvorianT.; CanellosG.P.; RitzJ.;Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.N. Engl. J. Med.316: 1499–1505; 1987.
42.
TsengA.Jr.; JacobsC.; ColemanC.N.;Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin.Cancer Treat. Rep.71: 659–660; 1987.
43.
TuraS.; MazzaP.; GherlinzoniF.;Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.Cancer Chemother. Pharmacol.23: 123–125; 1989.
44.
VelasquezW.S.; CabanillasF.; SalvadorP.;Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).Blood71: 117–122; 1988.
45.
VoseJ.M.; ArmitageJ.O.; BiermanP.J.;Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation.Am. J. Med.878: 285–288; 1989.
46.
WagemakerG.; VielangaJ.J.; BurgerM.;Quantitative approach to hemopoietic growth factor stimulated autologous hemopoietic regeneration in Rhesus monkeys. In: DickeK.A.; ArmitageJ.O., eds. Autologous bone marrow transplant patients.Omaha: University of Nebraska Press (in press).
47.
WarrellR.P.Jr.; DanieuL.; CoonleyC.J.; AtkinsC.Salvage chemotherapy of advanced lymphoma with investigational drugs: Mitoguazone, gallium nitrate, and etoposide.Cancer Treat. Rep.71: 47–51; 1987.
48.
WinterJ.N.; GordonL.I.; HauckW.W.; VariakojisD.Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes.Cancer Treat. Rep.70: 1243–1244; 1986.
49.
YoshidaT.; NakamuraS.; OhtakeS.;Salvage chemotherapy of refractory lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.Cancer Chemother. Pharmacol.25: 135–138; 1989.
